BioSpace News Archive

Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.

Today, NuvoAir Medical announced its innovative Air Next Spirometer has received formal 510(k) clearance for in-home use as a full spirometer.

Abdera Therapeutics Inc. today announced the appointments of Philippe Bishop, M.D., as chief medical officer and Eric Dobmeier as a member of the company’s board of directors.

Vect-Horus today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

INmune Bio Inc., a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with XProTM, a dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company’s AD clinical trial program has been lifted.

Vaxxinity, Inc. today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.

Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform.

ProSomnus, Inc. announced today that the United States Food and Drug Administration (the “FDA”) has accepted, and is in the process of reviewing, the Company’s premarket notification for its ProSomnus® EVO® precision medical device for the treatment of patients with severe obstructive sleep apnea.

Panbela Therapeutics, Inc today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024.